NCT01217931 - Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

January 19, 2011

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Kidney Cancer

Interventions

DRUG

Pazopanib

800 mg by mouth once daily for 28 days. A cycle consists of 4 weeks.

DRUG

Bevacizumab

10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.

DRUG

Everolimus

10 mg by mouth once daily. A cycle consists of 4 weeks.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston